BRAF and breast cancer: The high demanding metabolic cell lines used in this study were selected to cover a wide range of metastatic cancer features: The MCF-7 breast cancer cell line harbors estrogen receptors whereas MDA-MB-231 was triple-negative; the bone-metastatic PC-3 cell line was TP53 mutated, whereas the LNCaP metastatic cell line was androgen-dependent; finally, the considered BRAFV600E-mutated metastatic melanoma were either sensitive (451-Lu, M229) or resistant (D10) to the standard of care BRAF/MEK combined inhibitors.